Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK232802 for Vasomotor Symptoms in Postmenopausal Women
NCT00604825Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2007
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of GSK232802 in vasomotor symptoms (4 arms), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) up to 21 weeks, Mean Change in Frequency of Vasomotor Symptoms (VMS) From Baseline at Week 12 and 4 more. Started Jul 2007; status: completed.
02
Drugs
GSK232802
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT00604825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00604825.